{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:14:45Z","timestamp":1773281685057,"version":"3.50.1"},"reference-count":19,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1136\/bjophthalmol-2014-306341","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T00:02:19Z","timestamp":1428192139000},"page":"1334-1340","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Six-month changes in cytokine levels after intravitreal bevacizumab injection for diabetic macular oedema and macular oedema due to central retinal vein occlusion"],"prefix":"10.1136","volume":"99","author":[{"given":"Jing","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanrong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,4,3]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2014-306341-1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"key":"key-10.1136\/bjophthalmol-2014-306341-2","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1167\/iovs.09-4065","article-title":"Alterations in the intraocular cytokine milieu after intravitreal bevacizumab","volume":"51","author":"Forooghian","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2014-306341-3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jdiacomp.2013.09.010","article-title":"Vitreous biomarkers in diabetic retinopathy: a systematic review and meta-analysis","volume":"28","author":"McAuley","year":"2014","journal-title":"J Diabetes Complications"},{"key":"key-10.1136\/bjophthalmol-2014-306341-4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/157339906775473671","article-title":"Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy","volume":"2","author":"Simo","year":"2006","journal-title":"Curr Diabetes Rev"},{"key":"key-10.1136\/bjophthalmol-2014-306341-5","doi-asserted-by":"crossref","first-page":"e68149","DOI":"10.1371\/journal.pone.0068149","article-title":"Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion","volume":"8","author":"Feng","year":"2013","journal-title":"PLoS ONE"},{"key":"key-10.1136\/bjophthalmol-2014-306341-6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1167\/iovs.08-2510","article-title":"Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab","volume":"50","author":"Funk","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2014-306341-7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ajo.2011.03.007","article-title":"Intraocular expression of serum amyloid a and interleukin-6 in proliferative diabetic retinopathy","volume":"152","author":"Ma","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-306341-8","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1167\/iovs.10-6097","article-title":"Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion","volume":"52","author":"Wolf-Schnurrbusch","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2014-306341-9","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archophthalmol.2012.393","article-title":"A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3","volume":"130","author":"Rajendram","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-306341-10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10792-008-9242-2","article-title":"Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion","volume":"29","author":"Astam","year":"2009","journal-title":"Int Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-306341-11","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00417-007-0569-6","article-title":"Bevacizumab in retinal vein occlusion-results of a prospective case series","volume":"245","author":"Stahl","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-306341-12","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ophtha.2010.08.038","article-title":"Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications","volume":"118","author":"El-Sabagh","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-306341-13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cyto.2012.07.005","article-title":"Intravitreal bevacizumab increases intraocular interleukin-6 levels at 1 day after injection in patients with proliferative diabetic retinopathy","volume":"60","author":"Jeon","year":"2012","journal-title":"Cytokine"},{"key":"key-10.1136\/bjophthalmol-2014-306341-14","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1167\/iovs.13-13587","article-title":"Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion","volume":"55","author":"Jung","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2014-306341-15","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/j.1755-3768.2011.02292.x","article-title":"Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion","volume":"90","author":"Koss","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-306341-16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ajo.2011.03.033","article-title":"Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema","volume":"152","author":"Sohn","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-306341-17","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/bjophthalmol-2012-301913","article-title":"Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion","volume":"96","author":"Lee","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-306341-18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.preteyeres.2005.09.001","article-title":"The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells","volume":"25","author":"Harada","year":"2006","journal-title":"Prog Retin Eye Res"},{"key":"key-10.1136\/bjophthalmol-2014-306341-19","first-page":"2336","article-title":"TGF-beta 1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy","volume":"41","author":"Bochaton-Piallat","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2014-306341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:49:34Z","timestamp":1601110174000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2014-306341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,3]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,9,22]]},"published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1136\/bjophthalmol-2014-306341"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2014-306341","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,3]]}}}